Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$141.65 USD
-0.64 (-0.45%)
Updated May 20, 2024 04:00 PM ET
After-Market: $141.48 -0.17 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NBIX 141.65 -0.64(-0.45%)
Will NBIX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for NBIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NBIX
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
NBIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
Other News for NBIX
Interesting NBIX Put And Call Options For July 19th
Wall Street Analysts Are Bullish on Top Healthcare Picks
Neurocrine Biosciences Moves Up In Market Cap Rank, Passing Pool
Evercore says biotech ‘winter is finally thawing’
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024